Combination therapies for the treatment of HCV infection in a particular patient genetic subtypes subpopulations

摘要

The present invention treats HCV infection in patients with genetic alterations (including SNP rs12979860 having a non-CC genotype and SNP rs8099917 having a non-TT genotype) located near the IL28B gene, or one or more thereof Such therapeutic combinations and methods of use thereof are provided to alleviate the symptoms. The present invention relates to a therapeutic combination comprising (a) a compound (1), or a pharmaceutically acceptable salt thereof, (b) interferon alpha and (c) ribavirin as described herein. Compound (1) is a selective and potent inhibitor of HCV NS3 serine protease. [Selection figure] None